Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non–muscle-invasive Bladder Cancer
We compared outcomes for patients who received two different in-bladder treatments for intermediate-risk bladder cancer. Bacillus Calmette-Guérin (BCG) led to better outcomes than gemcitabine + docetaxel (Gem/Doce). Monthly maintenance therapy improved recurrence-free survival for patients who received Gem/Doce. We conclude that maintenance therapy is essential for patients receiving Gem/Doce to avoid bladder cancer recurrence after treatment.
Authors
- Peter N. Wiklund (ORCID: https://orcid.org/0000-0001-6497-4697)
- Reuben Ben‐David (ORCID: https://orcid.org/0000-0001-7946-7145)
- Kyrollis Attalla (ORCID: https://orcid.org/0000-0002-4707-9663)
- John P. Sfakianos (ORCID: https://orcid.org/0000-0002-3101-0266)
- Reza Mehrazin (ORCID: https://orcid.org/0009-0007-8648-0410)
- Parissa Alerasool
- Ahmed Eraky (ORCID: https://orcid.org/0000-0001-6879-6058)
- Sarah Lidagoster
- Neeraja Tillu
- Kaushik P. Kolanukuduru (ORCID: https://orcid.org/0009-0001-9525-2600)
- Mohammed Almoflihi
- Nikhil Waigankar
Institutions
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Urology Focus
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1016/j.euf.2024.09.006
- Citations
- 10
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.73